Cancer News and Research

Latest Cancer News and Research

Vical second-quarter revenues decrease to $2.1 million

Vical Incorporated today reported financial results for the three months and six months ended June 30, 2010. Revenues decreased to $2.1 million for the second quarter of 2010 from $4.0 million for the second quarter of 2009, primarily as a result of a $1.5 million milestone payment in 2009 from Merck & Co., Inc., based on Merck's ongoing Phase 1 clinical-stage development of an investigational cancer vaccine.

3 Aug 2010

Effects of natural compound against prostate cancer published in Integrative Cancer Therapies

Researchers at Columbia University have published the dramatic effects of a natural 33-ingredient compound against prostate cancer cell lines. The impressive results are found in the most recent publication of Integrative Cancer Therapies.

3 Aug 2010

Insulin resistance from obesity leads to lower cognitive performance in children: Research

A study by researchers at NYU Langone Medical Center have found that obese adolescents with type 2 diabetes have diminished cognitive performance and subtle abnormalities in the brain as detected by Magnetic Resonance Imaging (MRI). Identification of cognitive impairments as a complication of type 2 diabetes emphasizes the importance of addressing issues of inactivity and obesity, two important risk factors for the development of the disease among the young.

3 Aug 2010

First patient treated in Phase Ib expansion study of CUDC-101

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the first patient has been treated in a Phase Ib expansion study for CUDC-101 in patients with advanced head and neck, gastric, breast and liver cancers.

3 Aug 2010

NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM

Northwest Biotherapeutics, Inc. today announced further positive long-term follow-up data from its prior Phase I and Phase I/II clinical trials, in which patients with newly diagnosed Glioblastoma multiforme ("GBM"), the most rapid and lethal type of brain cancer, were treated with NWBT's DCVax®-Brain personalized immune therapy.

3 Aug 2010

U.S. clinical trials provide further evidence of importance of storing umbilical cord blood

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today said that clinical trials ongoing in the U.S. using umbilical cord blood in the treatment of cerebral palsy, high-risk hematologic cancer, injured spinal cords and Type 1 diabetes provide significant further evidence of the importance of storing umbilical cord blood at the time of birth.

3 Aug 2010

Scientists discover factors that reduce breast screening effectiveness

Scientists have found evidence that the reduced effectiveness of breast screening in women in their 40s is mainly due to their tumours being harder to detect, rather than because they grow faster.Previous research has suggested that breast screening is less effective in women in their 40s than in older women.Two reasons have been identified for this - firstly, that younger women tend to have denser breast tissue which makes it harder to detect tumours on a mammogram; and secondly, because younger women's tumours tend to grow more quickly.

3 Aug 2010

New trend in management of post-liver transplantation biliary strictures

Endoscopic intervention has emerged to become the first line treatment for benign biliary strictures following liver transplantation. The current endoscopic approach involves repetitive dilatation of the stricture and placement of multiple large-diameter parallel plastic stents with frequent stent exchange to prevent biliary infection.

3 Aug 2010

Research findings help shape long-term follow-up strategies for early stage lung cancer patients

In patients with non-small cell lung cancer, five-year disease-free survival is currently the benchmark of cure. However, there are two issues that remain with the follow-up standards: (1) When can cure be declared with confidence and (2) for how long should follow-up examination be continued?

3 Aug 2010

Study finds hunger as a serious risk factor for long-term poor health among children, youth

Children and youth who experience hunger appear more likely to have health problems, and repeated episodes of hunger may be particularly toxic, according to a report in the August issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

3 Aug 2010

Toxic protein in bee venom improves liposome encapsulated drug effectiveness

The next time you are stung by a bee, here's some consolation: a toxic protein in bee venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs or dyes, such as those already used to treat or diagnose cancer. This research, described in the August 2010 print issue of the FASEB Journal, shows how modified melittin may revolutionize treatments for cancer and perhaps other conditions, such as arthritis, cardiovascular disease, and serious infections.

3 Aug 2010

Antisense Pharma receives FDA IND authorisation for clinical studies with trabedersen for high-grade glioma

The biopharmaceutical company Antisense Pharma announced today that the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug (IND)-authorisation for clinical studies with trabedersen for patients with high-grade glioma. This authorisation entitles the company to include US-American clinics both in the phase III study SAPPHIRE and in further studies.

3 Aug 2010

New surgical technique to maximize preservation of periprostatic anatomy

Stress urinary incontinence is one of the most feared complications of radical prostatectomy. The weighted mean continence rate immediately after catheter removal following robot-assisted laparoscopic radical prostatectomy (RALP) is 25.7%. Evidently, early recovery of urinary continence remains a challenge to be overcome. The Surgery in Motion section of the September issue of European Urology describes the surgical steps of pubovesical complex (PVC)-sparing RALP and presents the preliminary results of the technique.

3 Aug 2010

Study shows prevalence, severity of dyspnea in long-term lung cancer survivors

With the growing number of long-term lung cancer survivors, research is needed to identify and address cancer survivorship issues. One of the most common and debilitating symptoms among lung cancer patients is dyspnea, or shortness of breath. As most studies of dyspnea have reviewed patients with active lung cancer or immediately after treatment, the prevalence of dyspnea over the long-term once treatment has been completed is not well characterized.

3 Aug 2010

Telormedix, Swiss TPH Institute collaborate to develop effective vaccines for Malaria, Buruli Ulcer

Telormedix, a clinical stage biopharmaceutical company using targeted immunity to treat cancer and other diseases, today announced the start of a collaboration with the Swiss Tropical and Public Health Institute (Swiss TPH) on a pilot study using Telormedix's adjuvant, TMX-201, in connection with immunization for Malaria and Buruli Ulcer.

3 Aug 2010

Particles of iron oxide enhance tumor visibility through MRI

Tiny particles of iron oxide could become tools for simultaneous tumor imaging and treatment, because of their magnetic properties and toxic effects against brain cancer cells. In mice, researchers from Emory University School of Medicine have demonstrated how these particles can deliver antibodies to implanted brain tumors, while enhancing tumor visibility via magnetic resonance imaging (MRI).

3 Aug 2010

ArQule, Daiichi Sankyo announce decision to advance ARQ 197 into Phase 3 clinical trial for NSCLC

ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced that they will move forward with a Phase 3 clinical trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with non-small cell lung cancer (NSCLC). In connection with this decision, the sponsor company, Daiichi Sankyo, will file a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for a trial comparing ARQ 197 plus erlotinib against erlotinib plus placebo.

3 Aug 2010

MRCC deploys CTT's Calmare Pain Therapy Treatment medical device

Competitive Technologies, Inc. announced that McKinney Regional Cancer Care Center, a private physician oncology practice based in McKinney, TX, is the first cancer center in Texas treating with CTT's Calmare Pain Therapy Treatment medical device. Patients suffering from pain related to cancer are being treated under the direction of medical oncologist Dennis Birenbaum, M.D.

3 Aug 2010

Study reveals potential marker for prostate cancer

Studies by a Purdue University-led team have revealed a potential marker for prostate cancer that could be the starting point for less invasive testing and improved diagnosis of the disease.

3 Aug 2010

NCI awards LSUHSC-NOLA Louisiana Tumor Registry $12 million SEER contract

The Louisiana Tumor Registry (LTR) at the LSU Health Sciences Center New Orleans School of Public Health has been awarded a $12 million contract over seven years by the National Cancer Institute to continue its work as a SEER (Surveillance, Epidemiology and End Results) Program-designated cancer registry. There are 18 competitively awarded SEER cancer registries in the United States.

3 Aug 2010

Cancer News and Research

Latest Cancer News and Research

Vical second-quarter revenues decrease to $2.1 million

Effects of natural compound against prostate cancer published in Integrative Cancer Therapies

Insulin resistance from obesity leads to lower cognitive performance in children: Research

First patient treated in Phase Ib expansion study of CUDC-101

NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM

U.S. clinical trials provide further evidence of importance of storing umbilical cord blood

Scientists discover factors that reduce breast screening effectiveness

New trend in management of post-liver transplantation biliary strictures

Research findings help shape long-term follow-up strategies for early stage lung cancer patients

Study finds hunger as a serious risk factor for long-term poor health among children, youth

Toxic protein in bee venom improves liposome encapsulated drug effectiveness

Antisense Pharma receives FDA IND authorisation for clinical studies with trabedersen for high-grade glioma

New surgical technique to maximize preservation of periprostatic anatomy

Study shows prevalence, severity of dyspnea in long-term lung cancer survivors

Telormedix, Swiss TPH Institute collaborate to develop effective vaccines for Malaria, Buruli Ulcer

Particles of iron oxide enhance tumor visibility through MRI

ArQule, Daiichi Sankyo announce decision to advance ARQ 197 into Phase 3 clinical trial for NSCLC

MRCC deploys CTT's Calmare Pain Therapy Treatment medical device

Study reveals potential marker for prostate cancer

NCI awards LSUHSC-NOLA Louisiana Tumor Registry $12 million SEER contract

Understanding the DNA Damage Response in Innate Immunity eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in